stability of plasma rich in growth 55 Sauer R, Blüthner K, Seitz B.

[Sterility of non-preserved autologous serum drops for

factors eye drops after storage of 3 months. Cornea
2013;32:1380–6. treatment of persistent corneal epithelial defects]. Ophthalmologe 2004;101:705–9.
73 Anitua E, Muruzabal F, De la fuente M, et al. Effects
of heat-treatment on plasma 56 Thanathanee O, Phanphruk W, Anutarapongpan O, et al. Contamination risk of
rich in growth factors-derived autologous eye drop. Exp
Eye Res 2014;119:27–34. 100% autologous serum eye drops in management of ocular surface diseases.
74 López-Plandolit S, Morales MC, Freire V, et al. Efficacy
of plasma rich in growth Cornea 2013;32:1116–19.
factors for the treatment of dry eye. Cornea
2011;30:1312–17. 57 Leite SC, De castro RS, Alves M, et al. Risk factors and characteristics of ocular
75 López-Plandolit S, Morales MC, Freire V, et al. Plasma
rich in growth factors complications, and efficacy of autologous serum tears after haematopoietic
as a therapeutic agent for persistent corneal epithelial
defects. Cornea progenitor cell transplantation. Bone Marrow Transplant 2006;38:223–7.
2010;29:843–8.
Soni NG, Jeng BH. Br J Ophthalmol 2016;100:22–27. doi:10.1136/bjophthalmol-2015-306842 27
group.bmj.com on July 10, 2017 - Published by http://bjo.bmj.com/ Downloaded from
iehirhfdhioeshrnfjszhcnksjiyehdsjgiuwgjsfbksjofpeojr

Review